Phase III trial comparing the efficacy and safety of recombinant- or urine-derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo-ovulation and undergoing ovulation induction with follitropin-alfa.

导出 LinkOut

翻译打印收藏纠错

作者： Hideyuki,Ikenaga ^[1] ; Yudai,Tanaka ^[2] ; Masahide,Shiotani ^[3] ; Daniela,Rogoff ^[4] ; Shin,Shimizu ^[5] ; Osamu,Ishihara ^[6] ; Yoshiaki,Sato ^[7] ; Yoshiharu,Morimoto ^[1] ; Aisaku,Fukuda ^[1] ; Kohzo,Aisaka ^[1] ; Koji,Yoshida ^[1] ; Naoki,Hayashi ^[1] ; Hirotsugu,Oku ^[1] ; Yuji,Abe ^[1] ; Atsushi,Haruki ^[1] ; Motoharu,Ishikawa ^[1] ; Takeshi,Kuramoto ^[1]

作者单位： Bashamichi Ladies Clinic Yokohama Japan. ^[1] Medical Park Shonan Fujisawa Japan. ^[2] Hanabusa Women's Central Fertility Clinic Kobe Japan. ^[3] EMD Serono Research & Development Institute, Inc. Billerica Massachusetts USA. ^[4] Present address: Versartis, Inc. Menlo Park CA USA. ^[5] Merck Serono Company, Ltd Tokyo Japan. ^[6] Saitama Medical University Hospital Saitama Japan. ^[7]

关键词 assisted reproductive techniques human chorionic gonadotropin oocyte retrieval ovulation ovulation induction

DOI 10.1002/rmb2.12008

PMID 29259450

发布时间 2021-01-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交